Back

Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial

7 April 2022 (09:30 - 14:00)
Organised by:
Congress Presentation Part of: Rapid fire abstracts session 1 - Secondary Prevention and Rehabilitation Pharmacotherapy EAPC Premium Access ESC Preventive Cardiology 2022

About the speaker

Photo
Doctor Ahmed A Kolkailah

University of Texas Southwestern Medical Center, Dallas (United States of America)

4 More presentations in this session

Presentation thumbnail
Ventricular-arterial coupling derived from proximal aortic stiffness: impact on aerobic capacity across the heart failure spectrum.
Doctor N. Pugliese (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitors in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis
Doctor V. Tsampasian (Norwich, GB)
Abstract Slides Video
Presentation thumbnail
High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort
Doctor P. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Insomnia was associated with increased risk of recurrent cardiovascular events in coronary heart disease patients
Mr L. Frojd (Drammen, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Rapid fire abstracts session 1 - Secondary Prevention and Rehabilitation

The Event

Event poster

ESC Preventive Cardiology 2022

7 April - 9 April 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources